Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data
Authors:
Open Access
- 1 January 2017
- journal article
- review article
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 2 (2_suppl) , S29-S35
Abstract
Systemic sclerosis (SSc) is an immune-mediated disease characterized by progressive, and often severe, inflammation and fibrosis of the skin and internal organs, such as the lungs, heart, kidneys, and gastrointestinal tract. There is an unmet medical need to treat patients with SSc given the high SSc-related mortality rate. Furthermore, disease-modifying therapies are lacking, and current treatment options focus on the management of individual organ-specific complications associated with the disease. Immunosuppressive therapies are the mainstay of pharmacologic management of major SSc-associated complications, such as skin and lung manifestations, but their overall effectiveness is limited and toxicity issues are common. Advances in understanding of the pathological processes involved in the immunologic and fibrotic mechanisms of SSc have led to clinical research focusing on targeted immunotherapies, in an effort to develop much needed disease-modifying treatment options. The interleukin-6 receptor-alpha antagonist tocilizumab has demonstrated promising efficacy in a phase 2 trial and is being investigated in a phase 3 trial. This article provides an overview of current pharmacologic treatment options for the management of SSc-related complications and discusses tocilizumab for the treatment of SSc in clinical trials.Keywords
This publication has 28 references indexed in Scilit:
- Epidemiology of systemic sclerosisBest Practice & Research Clinical Rheumatology, 2010
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumabRheumatology, 2010
- Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized sclerodermaExperimental Dermatology, 2009
- Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in SclerodermaThe Journal of Rheumatology, 2009
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosisArthritis & Rheumatism, 2007
- A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis & Rheumatism, 2006
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- COMPARISON OF METHOTREXATE WITH PLACEBO IN THE TREATMENT OF SYSTEMIC SCLEROSIS: A 24 WEEK RANDOMIZED DOUBLE-BLIND TRIAL, FOLLOWED BY A 24 WEEK OBSERVATIONAL TRIALRheumatology, 1996